看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
! }& s% T& E9 u9 o- A: m
" I) N. c& t8 z% I
% } |1 l5 Q# A& R) yCurrently available feasibility data for possible combination strategies.
1 o# T% G( A# i& W. M; t————————————————————————————————
6 H3 U G: X/ UCombination Feasibility according to preliminary data
. J2 U: q) n0 c& B7 E——————————————————————————————————6 m! p7 y# c8 j- K$ p v
Bevacizumab + sorafenib Yes, reduced dose 3 ~. o1 G1 |) i) }2 Q8 ~
Bevacizumab + sunitinib† No
1 W. _& y" E$ Z: F; t7 mBevacizumab + temsirolimus Yes 5 R! o2 Q7 A7 W$ {* \
Bevacizumab + everolimus Yes
# [* w( i3 l( L3 E6 ]Sorafenib + sunitinib ?
+ @ s! c" _( W$ u4 K! r, [+ C& ZSorafenib + temsirolimus Yes, reduced dose 5 H2 c" E- }2 J5 C! J+ Q1 K% {* b) H
Sorafenib + everolimus Yes, reduced dose
# Q- E: U, o" k8 B. Z$ `Sunitinib + temsirolimus† No
7 b5 J) M4 @, C7 z; DSunitinib + everolimus ? 7 ?7 b4 o+ N0 N3 V! {) i9 p
Temsirolimus + everolimus ? $ P4 ]4 l) x+ @9 [, `' Q) |
————————————————————
# \* S1 K, d' N†Led to US FDA warning.
- C! M; m/ N" h?: As yet unattempted combination." i* K* R; G y* ~ ^
|